<DOC>
	<DOCNO>NCT02225327</DOCNO>
	<brief_summary>Similar child , adult frequently visit outpatient clinic get two kind vaccines time : pneumococcal vaccine , influenza vaccine , Td ( diphtheria tetanus ) vaccine , HPV ( human papilloma virus ) vaccine , meningococcal vaccine , zoster vaccine , etc . This study intend evaluate immunogenicity safety concomitant administration 23-valent pneumococcal polysaccharide vaccine ( PPV23 , Prodiax ) MF59 adjuvanted trivalent influenza vaccine elderly subject age ≥65 year .</brief_summary>
	<brief_title>MF59-adjuvanted Influenza Vaccine 23-valent Pneumococcal Polysaccharide Vaccine</brief_title>
	<detailed_description>During influenza season , concomitant influenza pneumococcal vaccination would effective strategy enhance pneumococcal vaccine coverage rate high-risk adult . However , immunogenicity safety concomitant vaccination need investigate . There data immunogenicity safety concomitant administration pneumococcal polysaccharide vaccine ( PPV ) unadjuvanted influenza vaccine ; interference note two vaccine . However , data MF59 adjuvanted influenza vaccine pneumococcal vaccine . MF59 locally react immune response , immunogenicity assess vaccine inject arm versus different arm . This study intend evaluate immunogenicity safety concomitant MF59-adjuvanted trivalent influenza vaccine ( MF59-aTIV , Fluad ) 23-valent pneumococcal polysaccharide vaccine ( PPV23 , Prodiax ) vaccination elderly subject age ≥65 year . Healthy elderly subject ( N = 424 ) randomize 1:1:1:1 ratio receive MF59-aTIV alone ( group 1 ) , MF59-aTIV +PPV23 different arm ( group 2 ) , MF59-aTIV +PPV23 arm ( group 3 ) PPV23 alone ( group 4 ) . Hemagglutination inhibition ( HI ) assay multiplex opsono-phagocytic kill assay ( MOPA ) use compare immunogenicity vaccine single concomitant vaccination pre-vaccination 1 month post-vaccination . MOPA take four serotypes ( 5 , 6B , 18C 19A ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>At least 65 year age eligible study vaccine ; Who give write informed consent time enrollment ) ; Those available visit schedule study ; Subjects In good health determine medical history , physical examination clinical judgment investigator History egg allergy History influenza vaccination previous 6 month History pneumococcal vaccination Documented S. pneumonia infection previous 5 year Chemotherapy malignancy within past 30 day Highdose systemic steroid ( prednisone ≥0.5 mg/kg/day ) past 30 day Receipt blood product within 6 month enrollment Significant acute chronic infection within previous 7 day fever within previous day Any serious chronic progressive disease Any condition might interfere study result .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>